Celgene Corporation (NASDAQ:CELG)‘s stock had its “buy” rating restated by equities research analysts at Bank of America Corporation in a research report issued on Monday. They currently have a $153.00 target price on the biopharmaceutical company’s stock. Bank of America Corporation’s price objective suggests a potential upside of 15.97% from the company’s current price.

Several other research analysts also recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $138.00 price target on shares of Celgene Corporation in a research report on Wednesday, May 24th. Leerink Swann reaffirmed a “market perform” rating on shares of Celgene Corporation in a research report on Monday, March 20th. Cann reaffirmed a “buy” rating and issued a $148.00 price target on shares of Celgene Corporation in a research report on Tuesday, April 4th. Argus downgraded Celgene Corporation from a “buy” rating to a “hold” rating and lifted their price target for the stock from $123.91 to $124.46 in a research report on Friday, May 5th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $140.80.

Celgene Corporation (NASDAQ:CELG) traded down 0.48% during mid-day trading on Monday, hitting $131.93. 2,439,544 shares of the stock were exchanged. The company has a market cap of $103.01 billion, a P/E ratio of 49.54 and a beta of 1.89. Celgene Corporation has a one year low of $96.93 and a one year high of $135.18. The company has a 50-day moving average price of $121.46 and a 200-day moving average price of $120.59.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.47 by $0.21. Celgene Corporation had a return on equity of 70.94% and a net margin of 18.32%. The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.04 billion. During the same period in the previous year, the company earned $1.32 EPS. The company’s revenue for the quarter was up 17.8% on a year-over-year basis. On average, analysts predict that Celgene Corporation will post $7.29 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Celgene Corporation (NASDAQ:CELG) Rating Reiterated by Bank of America Corporation” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/10/celgene-corporation-nasdaqcelg-rating-reiterated-by-bank-of-america-corporation.html.

In related news, Director James J. Loughlin sold 18,500 shares of the company’s stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $133.57, for a total value of $2,471,045.00. Following the completion of the sale, the director now owns 32,877 shares in the company, valued at $4,391,380.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the sale, the insider now owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders sold 237,005 shares of company stock valued at $31,515,142 in the last quarter. 0.95% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Diversified Trust Co increased its stake in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares during the period. Sowell Financial Services LLC increased its stake in shares of Celgene Corporation by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares during the period. South Texas Money Management Ltd. increased its stake in shares of Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares during the period. Flagship Harbor Advisors LLC increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares during the period. Finally, Keel Point LLC increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares during the period. Institutional investors own 78.26% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.